Table 2.

Authorized/approved vaccines in at least one country as per 15 November 2021.

No	Vaccine Name	Status	Developer	Vaccine Type	Efficacy	Dose	Storage	Price (per Dose)	Source
1	ComirnatyTM (BNT162b2)	Approved in several countries, emergency use in US, elsewhere	Pfizer-BioNTech Germany-US	RNA based vaccine	95% [83]	2 dose, 3 weeks apart [84]	−70 °C [85]	€19.50 (US$23.15) [86]	[56]
2	Moderna mRNA-1273 and mRNA-1273.351	Approved in Switzerland, emergency use in US, elsewhere	ModernaTX, Inc US	RNA based vaccine	94.1% [87]	2 doses, 4 weeks apart [88]	−25 °C [89]	US$25.50 [86]	[56]
3	AstraZeneca AZD1222	Approved in Brazil, emergency use in EU, elsewhere	The University of Oxford-AstraZeneca UK	Viral vector (non-replicating)	76% [90]	2 doses, between four and 12 weeks apart [91]	2–8 °C [85]	US$2.15 (EU), US$5.25 (others) [92]	[56]
4	ConvideciaTM (Ad5-nCoV)	Approved in China, emergency use in other countries	CanSino Biologics China	Viral vector (non-replicating)	65.28%	Single dose	2–8 °C [93]	US$27.15 (Pakistan) [94]	[56]
5	Ad26.COV2.S	Emergency use in US, elsewhere	Janssen (Johnson & Johnson) US	Viral vector (non-replicating)	66.9% [95]	Single dose [95]	2–8 °C [85]	US$10 [96]	[56]
6	BBIBP-CorV	Approved in China, Bahrain, UAE, emergency use in other countries	Sinopharm (Beijing) China	Inactivated virus	79% [97]	2 doses, 3 weeks apart [98]	2–8 °C [99]	US$37.50 (Hungary) [100]	[56]
7	Inactivated SARS-CoV-2 (vero cell)	Approved in China, Limited use in UAE	Sinopharn + Wuhan Institute of Biological Products China	Inactivated virus	72.8%	2 doses, 3 weeks apart	2–8 °C	N/A	[56]
8	CoronaVac	Approved in China, emergency use in other countries	Sinovac China	Inactivated virus	51% in Brazil trial, 84% in Turkey trial [99]	2 doses, 2 weeks apart [99]	2–8 °C [89]	US$13.60 (Indonesia) [101]	[56]
9	Sputnik V	Emergency use in Russia, elsewhere	The Gamaleya Research Institute Russia	Viral vector (non-replicating)	91.6%	2 doses, 3 weeks apart	−18 °C [89]	Less than US$10 [102]	[103]
10	EpiVacCorona	Approved in Turkmenistan, early use in Russia	FBRI Russia	Protein subunit	N/A	2 doses, 3 weeks apart	2–8 °C	US$11 [104]	[103]
11	ZF2001/RBD-Dimer	Emergency use in China, Uzbekistan	Anhui Zhifei Longcom China	Protein subunit	N/A	3 doses, 4 weeks apart	2–8 °C	N/A	[103]
12	Soberana 2/Pasteur	Emergency use in Iran, Cuba	Instituto Finlay de Vacunas Cuba	Protein subunit	62% two doses, 91.2% with Soberana Plus	2 doses, 4 weeks apart	2–8 °C	N/A	[103]
13	Abdala/CIGB-66	Emergency use in Cuba	Center for Genetic Engineering and Biotechnology (CIGB) Cuba	Protein subunit	92.28%	3 doses, 2 weeks apart	2–8 °C	N/A	[103]
14	Medigen	Emergency use in Taiwan	Medigen Vaccine Biologics Taiwan	Protein subunit	N/A	2 doses, 4 weeks apart	2–8 °C	N/A	[56]
15	Covaxin®	Emergency use in India, elsewhere	Bharat Biotech India	Inactivated virus	77.8%	2 doses, 4 weeks apart	At least a week at room temperature	US$16.42 (India) [105]	[103]
16	QazCovid-in®	Early use in Kazakhstan	Research Institute for Biological Safety Problems Kazakhstan	Inactivated virus	N/A	1 or 2 doses, 3 weeks apart	2–8 °C	US$4.7 [106]	[103]
17	Inactivated (Vero Cells)	Emergency use in China	Shenzhen Kangtai Biological Products Co., Ltd. China	Inactivated virus	N/A	2 doses, 4 weeks apart	2–8 °C	N/A	[103]
18	COVIran Barekat	Emergency use in Iran	Shifa Pharmed ParsIran	Inactivated virus	N/A	2 doses	2–8 °C	N/A	[103]
19	CoviVac	Early use in Russia	Chumakov Cente Russia	Inactivated virus	N/A	N/A	2–8 °C	N/A	[103]
20	NVX-CoV2373	Emergency use in Indonesia	Novavax US	Protein subunit	89.7%	2 doses, 3 weeks apart	2–8 °C	US$20.90 (Denmark) [86]	[103]
21	ZyCoV-D	Emergency use in India	Zydus CadilaIndia	DNA based vaccine	66.6%	3 doses, 4 weeks apart	2–8 °C	N/A	[103]
22	COVAX-19®	Emergency use in Iran	Vaxine Pty.Ltd/Cinnagen Co. Australia	Protein Subunit	N/A	2 doses, 3 weeks apart	N/A	N/A	[103]
23	Soberana Plus	Emergency use in Cuba	Instituto Finlay de Vacunas Cuba	Protein subunit	N/A	N/A	N/A	N/A	[103]